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There is an urgent need for earlier diagnosis of malignancies and more stringent monitoring of relapses after antitumor
therapy. In addition, new prognostic markers are needed for risk stratiﬁcation and design of individualized cancer therapies.
New diagnostic and prognostic parameters should overcome the impairments of current standards in a cost-eﬀective manner.
Serologicalapproaches measuringspontaneousantibody responsesagainsttumor-associatedantigenscouldbe ofuseasdiagnostic
and prognostic markers and could also be employed to evaluate response to therapy in cancer patients. Autoantibodies have
been suggested to be of frequent and speciﬁc occurrence in patients with malignancies and to correlate with clinical parameters.
Screening the relevant literature on this topic, we suggest that the analysis of single antibody speciﬁcities is unlikely to provide
suﬃcient diagnostic and prognostic accuracy. The combined analysisof autoantibodies targeting diﬀerent antigens, however, may
reach high sensitivity and speciﬁcity. In addition, screening cancer patients for autoantibodies might identify subgroups with high
relapse risk and a worse prognosis.Larger prospective trials should be initiated to identify sets oftumor-associated autoantibodies
suited for the use in diagnostic algorithms for cancer detection and followup.
1.Introduction
For close to 150 years, human malignancies and the immune
system have been suspected to be interaction partners [1].
While data supporting this relationship has accumulated
in recent years, the exact biological role of spontaneously
occurring anti-tumor immune responses is still a matter of
controversy [2, 3]. In any case, the characterization of the
crosstalk between tumors and their immune environment
has led to a systematic analysis of the antibody repertoire of
cancer patients [4]. The relatively high frequency of spon-
taneous antibody responses against cancer-related antigens
led to the assumption that these antibodies could be of
use in the clinical setting [5]. Accordingly, a lot of eﬀort
was invested in correlating the presence of such antibodies
with clinical parameters to assess their use as prognostic
parameters. Furthermore, the highly cancer-speciﬁc nature
of some of these antibodies resulted in the evaluation of
their diagnostic utility [6]. Both approaches seemed very
promising asaserologicaldetectionofcancer,andaserologic
risk stratiﬁcation would be easy to handle, of low cost, and
much more likely to be accepted by a wide majority of
patients hesitant to undergo invasive procedures [7].
Nevertheless, the initial euphoria was dampened by
controversial results regarding the prognostic reliability of
tumor-associated autoantibodies throughout diﬀerent can-
cers [8]. Autoantibodies were either reported to improve the
prognosis of cancer patients, to worsen the clinical outcome,
oreventobeirrelevant forthecourseofthedisease[9].From
a diagnostic point of view, the results did not meet the high
expectations perhaps as the analysis of single autoantibodies
proved tobe ofinsuﬃcient sensitivity forclinical routine [8].
Very recently, the idea that tumor-associated autoanti-
bodies could be developed into meaningful diagnostic and
prognostic tools has been revived [10, 11] as researchers
aimed at increasing the sensitivity of serological assays2 Clinical and Developmental Immunology
by combining several autoantibodies [12]. In the present
paper, we will try to answer the question whether and how
autoantibodies could be used to enhance early diagnosis
of malignant conditions and how they might contribute to
perform appropriate risk stratiﬁcations in these patients.
2.SerologicalAnalyses inCancerPatients
2.1. Tumor-Associated Autoantibodies against Single Antigens
Lack Sensitivity to Reach Diagnostic Relevance. Since tumor-
associated autologous antibodies have ﬁrst been observed, it
has been investigated whether they could be used as an early
disease marker in a minimally invasive diagnostic approach
[6]. In order to be applicable as diagnostic markers, tumor-
associated autoantibodies should only be present in cancer
patients, they should be detectable in as many patients as
possible, and they should ideally appear early in the course
of the disease.
Choosing an appropriate antigen is a diﬃcult task in
light of the overwhelming amount of antigens eliciting
autoantibodies in cancer patients. The Cancer Immunome
Database [13] currently lists 2,743 sequences for 2,316
clones, and this number is constantly growing. However,
mostantigensare unsuitablefordiagnosticpurposesbecause
they are too low-titered, occur only in a subgroup of cancer
patients, and/orare also found inhealthy subjectsorpatients
with benign diseases [14].
We screened all available studies evaluating autoantibod-
i e sa sp o s s i b l ed i a g n o s t i cp a r a m e t e r si nc a n c e rp a t i e n t si n
the pubmed database. Autoantibodies had to be investigated
in at least ﬁve studies in order to be included into the ﬁnal
analysis.Weproposedthreequalitycriteriaforthe9antibody
speciﬁcities which were analyzed for their diagnostic value.
At least two of these criteria had to be fulﬁlled by a certain
antibody in order to qualify as a promising candidate for
diagnostic purposes. Serological responses (1) had to be
high-titered (deﬁned as a titer above 1:1,000), (2) had to
be detectable in at least 40% of patients with a respective
malignancy, and (3) had to be absent from the peripheral
blood of healthy subjects. Only three types of antibodies
fulﬁlled our quality criteria: polymorphic epithelial mucin
(MUC-1), p53, and Sry-like high mobility group super
family (SOX).
MUC-1 is overexpressed by breast, colorectal, and lung
cancer and is deﬁciently glycosylated on the cell surface
[15]. As a surface antigen, the immunogenicity of MUC-1
was of particular interest and has been extensively studied
[16, 17]. Despite the fact that high-titered MUC-1-speciﬁc
autoantibodies are frequently found in cancer patients, their
u s ea ss i n g l ed i a g n o s t i cp a r a m e t e r si sh a m p e r e db yt h e
circumstance that they can be detected at an almost similar
frequency in healthy donors [18].
In contrast, in a study examining patients with lung
cancer, p53-speciﬁc autoantibodies could be observed years
prior to detection of malignant lesions [8]. All patients
developed cancer after ﬁrst detection of anti-p53 autoan-
tibodies and the serological response remained detectable
throughout the remaining course of the disease [8]I nl i g h t
of such data, p53-speciﬁc autoantibodies would seem to
be very well suited for diagnostic purposes [19, 20]a n d ,
accordingly, anti-p53 autoantibodies have been extensively
studied regarding their diagnostic and prognostic applicabil-
ityfora widevarietyofmalignancies[21–23].Unfortunately,
one conclusion from these investigations is that screening
for anti-p53 antibodies—at least when used as a single
antigen—is of insuﬃcient sensitivity, which is indicated by
a maximal cancer detection rate of 46% [24]. In addition,
p53 antibodies are not restricted to a single cancer type [23]
and the observation that anti-p53 antibodies are detectable
in subgroups of patients with inﬂammatory diseases who
never develop a malignancy represents another important
downside of the use of p53 serology for diagnostic purposes.
Antibodies against SOX families B1 and B2 are found
[25] in up to 43% of patients with small cell lung cancer
(SCLC) [10]. Unfortunately, the presence of SOX-speciﬁc
antibodies in patients with benign diseases [10, 26]r e s u l t s
in an insuﬃcient speciﬁcity of SOX when used as a single
antibody. Anti-SOX antibodies have recently been suggested
to help diﬀerentiating between patients with paraneoplastic
(cancer associated) and sporadic Lambert-Eaton syndrome,
respectively [10]. On the other hand, many tumor patients
will evidence SOX antibodies without any hint for neuro-
logical symptoms [25]. Additional well-designed studies are
needed before the question whether anti-SOX antibodies are
usable for diagnostic purposes can be resolved.
Averyrecentmeta-analysis[27]hasconcludedthatEBV-
speciﬁc antibodiesare ofdiagnosticvalueforthediagnosis of
nasopharyngeal carcinoma. Speciﬁcity and sensitivity were
suggested to be extremely high for a single antigen (over
90%). However, these retrospective analyses still need to be
validated in a prospective manner. At this time, one has
to conclude that antibodies with a single speciﬁcity cannot
reliably be used for cancer screening and early detection.
2.2. The Combination of TumorAntigen-Speciﬁc Autoantibod-
ies May Reach Diagnostic Relevance. As a single cancer type
potentially elicits antibody responses against a large number
of antigens, another approach is to combine several types of
antibody responses in a diagnostic algorithm. Sucha strategy
should allow for increased sensitivity without signiﬁcantly
complicating the diagnostic procedure. However, as of yet
only a small number of studies has addressed this issue.
We will herein only discuss combinations of antibody
speciﬁcities (1) showing a speciﬁcity of at least 75% being
investigated in studies (2) including at least 100 patients.
Most published studies did not fulﬁll these criteria (Table 1).
Most of these studies used samples of patients in whom the
diagnosis of cancer had already been established.
It has recently been shown that up to 75% of all
breast cancer patients bear antibodies against at least one
of the following antigens: p53, c-myc, NY-ESO-1, BRCA1,
BRCA2, HER2, or MUC1. With a combined analysis of
these antibodies, speciﬁcity for breast cancer increased to
85% while sensitivity remained relatively low with 64% [17].
On the other hand, the combined analysis of antibodies
to p53, HER-2 (Human Epidermal growth factor Receptor-
2), IGFBP-2 (Insulin like Growth Factor Binding Protein
2), and TOPO2α (Topoisomerase-2-alpha) increased bothClinical and Developmental Immunology 3
Table 1: Combinations of autoantibodies evaluated as diagnostic measures.
Antibody speciﬁcity Number of patients Tumor type Speciﬁcity/Sensitivitiy Ref.
PIM1, MAPKAPK3, ACVR2B 114 Colon cancer 74/83 [28]
ASB-9, SERAC1, RELT 87 Breast cancer 100/80 [29]
PPIA, PRDX2, FKBP52, MUC-1, HSP60 142 Breast cancer 73/85 [30]
Calnuc, p53, Cyclin D1, Cyclin B1, myc 447 Mixed 59/62 [31]
myc, p53, Cyclin B1, p62, Koc, IMP1, Survivin 976 Mixed 50/91 [22]
CCCAP, HDAC5, p53, NMDAR, NY-CO-16 94 Colon cancer 59/78 [32]
SEREX clones (N = 6) 48 Colon cancer 96/92 [33]
SEREX clones (N = 10) 77 HCC 87/66 [34]
Imp1, p62, Koc, p53, myc, Cyclin B1, Survivin, p16 142 HCC 50/60 [35]
SEREX clones (N = 80) 39 Head and neck cancer 90/80 [36]
O-glycopeptides 56 Mixed 85/25 [37]
Nucleophosmin, Cathepsin D, p53, SSX 125 Ovarian cancer NN [38]
Autoantibodies to MIAPACA cell line 238 Pancreatic cancer 80/93 [39]
Phage display clones (N = 22) 119 Prostate cancer 88/82 [40]
p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2, MUC1 97 Breast cancer 85/64 [17]
p53, NY-ESO-1, CAGE; GBU4-5, Annexin 1 626 Lung cancer 90/40 [41]
diagnostic speciﬁcity and sensitivity to up to 75% for breast
cancer patients [12].
Combined serological approaches have also been applied
to other malignancies. Using lysates of a human pancreatic
carcinoma cell line as a mixture of unknown target antigens,
antibody responses were detected in over 90% of patients
with pancreatic cancer with a speciﬁcity of 80% [39, 42]. In
another study 22 phage-displayed tumor-associated antigens
were combined to diagnose prostate cancer in a serological
analysis. Sensitivity of this approach was remarkably high
with 88% while still detecting 82% of true-positive patients
[40]. Very recently, a large study including over 600 patients
with lung cancer and utilizing a combination of ﬁve antigens
reached a remarkable 90% speciﬁcity, while sensitivity
remained relatively low with 40% [41].
In conclusion, the combined analysis of diﬀerent tumor-
relatedautoantibodiesmightrepresentapromisingapproach
for the diagnosis of cancer leading to an up to threefold
increase in speciﬁcity and sensitivity (Table 1). However,
despite the general scalability of this approach, increasing
costs and the methodological complexicity of large antibody
screens become important considerations. To be applicable
in the clinical setting, standardized and reliable methods
for the performance of serological concepts are needed.
Unfortunately, a large variety of diﬀerent methods for
antibodydetectionhasbeenusedworldwideandresultsfrom
these analyses are often diﬃcult to compare [43]. Recently,
a semiautomatic ELISA assay has been proposed to possess
high speciﬁcity, reproducibility, and reliability [41]. The
broad introduction of comparable methods probably repre-
sents a prerequisite for the future use of serological analyses
of antibodies in clinical routine. Comprehensive prospective
studies are needed to provide a deﬁnitive rationale for their
application in the clinical routine.
2.3. Tumor-Related Autoantibodies Are Predictors of Clinical
Outcome in Cancer Patients. In spite of signiﬁcant progress
in the diagnosis and followup of cancer patients, it is
still diﬃcult to stratify patients according to their risk of
relapse [11]. Such an assessment would be of great use to
both patient and clinician, as it would help to diﬀerentiate
between those who might beneﬁt from additional therapy
and those who may only suﬀer from therapy-related side
eﬀects without achieving an improved outcome. An ideal
stratiﬁcation technique would also be of low cost and cause
minimal discomfort for the patient. Obviously, a serological
approach can fulﬁll both of these criteria and add further
diagnostic aspects not covered by current stratiﬁcations.
Many studies have examined the correlation between the
occurrence of tumor-related autoantibodies and the clinical
outcome of cancer patients (Table 2). When we screened the
literature, we focused on three types of target antigens: (1)
shared cancer-speciﬁc antigens, (2) antigens overexpressed
in tumors compared to normal tissues, and (3) mutated
antigens. Overall, among the studies dealing with the
prognostic impact of autoantibodies in cancer patients, 50%
were unable to demonstrate an impact on the course of the
disease, 33.33% did show a worse outcome, and 16.67%
involved a better prognosis.
A large body of studies particularly involving SEREX
(Serological Identiﬁcation of antigens by recombinant
expression cloning) identiﬁed antibodies that did not reveal
any signiﬁcant impact on clinical outcome. Even antibodies
against antigens that are involved in the pathogenesis of the
disease (Cyclin B1 or p53 in oral cancer) or associated with
a more aggressive course did not seem to aﬀect the outcome
(Table 2).
Antigen p53 probably represents the tumor-associated
protein that has most extensively been studied with regard4 Clinical and Developmental Immunology
Table 2: Inﬂuence of autoantibodies against tumor-associated antigens on the prognosis of cancer patients.
Autoantibody speciﬁcity Number of patients Tumor type Impact Ref.
Laminin 71 Breast cancer Decreased OS [44]
HSP90 327 Breast cancer Decreased OS [45]
p53 9489 Breast, gastric, colon cancer, NSCLC and oral cancer Decreased OS [46]
NY-ESO-1 207 Prostate cancer Decreased OS [47]
Nucleophosmin 100 Breast cancer Decreased RFS [48]
Panel of 29 antigens 60/59 Ovarian cancer/pancreatic cancer Increased OS [49]
CTSP-1 147 Prostate cancer Increased RFS [50]
p53 130 HCC Increased RFS [51]
Laminin-Receptor 67 CLL Increased RFS [52]
CML66 15 CML Increased RFS [53]
GLEA3 and PHF3 62 Glioblastoma Increased OS [54]
MUC1 30 NSCLC Increased RFS [18]
MUC1 100 Ovarian cancer Increased OS [55]
MUC5AC 30 Colon cancer Increased OS [56]
SOX1 90 SCLC Increased OS [57]
CEA 52 Breast cancer Increased RFS [58]
SEREX clones 12 Meningioma None [59]
SCP1 100 Pancreatic cancer None [60]
Cyclin B1 42 AML None [61]
p53 120 Oral cancer None [6]
Hsp90 116 Ovarian cancer None [62]
ALK 21 ALL None [63]
SEREX clones 25 SCC None [64]
MUC-1 125 Breast cancer None [65]
Survivin 76 NSCLC None [66]
NY-ESO-1 12 Diﬀerent cancers None [67]
NY-ESO-1 69 Esophageal cancer None [68]
Phage Display clones 176 Breast cancer None [69]
Braf 372 Melanoma None [70]
OS: overall survival, RFS: recurrence-free survival.
to its prognostic value. Several small studies yielded variable
results, ranging between a missing eﬀect and a negative
inﬂuence on the patients’ outcome [71]. Interestingly, one
larger study performed in hepatocellular carcinoma patients
suggested that the presence of p53-speciﬁc antibodies might
be associated with an increased overall survival [72]. How-
ever, a number of other large studies in breast, lung,
colon and oral cancer patients as well as a meta-analysis
clearly highlighted the correlation between the presence
of p53-speciﬁc autoantibodies and decreased overall and
progression-free survival [19, 73].
Another well-studied example of antibody responses
associated with a poor prognosis is found among Cancer
Testis Antigens (CTA). CTA, also called shared cancer-
speciﬁc antigens, represent a unique class of tumor proteins
with an expression restricted to normal testis and cancer
tissue. Interestingly, antibodies against some CTA, such as
NY-ESO-1, were primarily found in patients with advanced
disease [74].Levelsof NY-ESO-1-speciﬁc antibody responses
seemed to correlate with the volume of tumor tissue present
in the patient’s body [67]. Accordingly, spontaneous occur-
rence of NY-ESO-1 antibodies has particularly been found
in multiple myeloma patients and melanoma patients who
relapsed and/or suﬀered from progressive disease [67, 75].
Moreover, in prostate cancer, the presence of anti-NY-ESO-
1 antibodies was associated with a decreased overall survival
while no inﬂuence of NY-ESO-1 seropositivity was observed
in patients with esophageal cancer [47, 68]. These ﬁndings
might,ontheonehand,suggestthatNY-ESO-1-speciﬁcanti-
bodies merely represent markers of an increased tumor load
and donot indicate a biologicallyrelevant immune response.
Conversely,NY-ESO-1-speciﬁc antibodies mightin fact exert
ar e l e v a n ta n t i - t u m o re ﬀect by directly and/or indirectly
suppressing tumor growth in earlier stages of the disease.
As the disease progresses, the net eﬀects of these cancer-
speciﬁc immune responses might decrease and, ﬁnally, they
will be overwhelmed by cancer-related immunosuppression
and the kinetics of tumor growth [67]. This hypothesis
would, to some degree, be supported by observations in
patients vaccinated with CTA where response to therapy andClinical and Developmental Immunology 5
enhanced overall survival have been associated with CTA-
speciﬁc T cell and antibody responses [76].
On the other hand, a number of studies have suggested
a positive inﬂuence of the occurrence of tumor-associated
autoantibodies on the outcome of the patient. In one
study with NSCLC patients, the presence of anti-MUC-1
antibodies was clearly linked to earlier stages of the disease
as well as a lower recurrence rate [15]. Based on these
ﬁndings and on in vitro data, it was hypothesized that
spontaneously occurringanti-MUC-1antibodiesmight bind
to the surface of tumor cells uncovering adhesion molecules
masked by the deﬁciently glycosylated MUC-1. According
to this hypothesis, this would then render MUC-1 speciﬁc
antibodies a part of an eﬀective immune response against
cancer cells.
Compared to the overall number of studies analyzing
autoantibody proﬁles in cancer patients, relatively few
studies evaluate the impact of these immune responses
on the patients’ prognosis. This observation may be an
expression of publication bias, as negative results are less
likely to be reported than positive ones [77]. Accordingly,
controversial results are found even for a given antigen [19].
In contrast, antigens such as p53 or MUC-1 are well studied
in large cohorts and results may be considered reliable.
Accordingly, even if most studies suggest for autoantibodies
to have no impact on the course of human malignancies,
conﬁrmation oftheseresultsisstrongly needed.Importantly,
no study has yet revealed how such antibodies impact on the
patient’s prognosis, and it is unclear whether autoantibodies
themselves actively contribute to the patient’s outcome or
whether they are only an indicator of the clinical condition.
As in the case of diagnostic approaches, one could
theoretically analyze antibody responses against diﬀerent
antigens in a combined manner in order to enhance the
prognostic impact of such assays. A very recent work
by Gnjatic et al. has addressed this issue and found the
simultaneous presence of four diﬀerent autoantibodies to
deﬁne a subgroup of patients who showed an improved
prognosis [49]. This pioneering work might lead the way
towards a more eﬃcient prognostic classiﬁcation of cancer
patients based on serological analyses.
Unfortunately, to date little is known regarding the
behavior of humoral responses against tumor antigens over
the course of the disease. In the vaccination setting antibody
responses have been routinely monitored over time, but
longitudinal studies on spontaneously occurring antibody
responses are scarce [78] .T h ef e wd a t aa v a i l a b l es u g g e s t
that, for example, the appearance and persistence of NY-
ESO-1-speciﬁc antibodies are tightly linked to the amount
of antigen present in the patient’s body. Accordingly, disease
progression appears to promote the development of NY-
ESO-1-speciﬁc antibody responses and to lead to increased
antibody titers. Future studies will have to determine in a
stringent manner the clinical conditions contributing to the
development of autoantibodies in cancer patients.
In any case, the biological basis of either of these obser-
vations remains elusive. Therefore, although it is impossible
to design randomized studies in this particular setting,
prospective analysesevaluating such antibody responses over
the course of the patient’s disease may help to address
two related questions: (1) under which clinical situations
does thepatientdevelopantibodies against tumor-associated
antigens and (2) what is the temporal association between
clinicalincidents(i.e.,response totherapyorrelapse)andthe
development of humoral immune responses.
3.Conclusions
The large diversityoftheantibody repertoire directed against
autologous tumor-related antigens illustrates the complex
and heterogeneous nature of the human seromic repertoire.
As summarized in this analysis, the combination of a few
frequentlyoccurringtypesofantibodiesmaybeofdiagnostic
value for certain malignancies. The combination approach
appears particularly attractive because of the lack of sec-
ondary prevention tools for many tumor types. However,
prospective studies evaluating the true value of this method
are required prior to clinical introduction.
As primary cancer prevention remains a frustrating issue
due to the multifactorial origins of cancer, early detection of
cancer lesions is an essential goal to enhance the patient’s
prognosis and to reduce costs. Current strategies focus on
apparative diagnostics and only to a much lesser extend
on serological testing [79, 80]. As of yet, only mammog-
raphy, colonoscopy, cervical smear, and skin examination
are accepted early cancer detection tools for the respective
cancer types [79, 81–83]. While the reduction in overall
mortality provided by these screening methods alone is not
well deﬁned, speciﬁcity and the sensitivity reach almost 90%
in given studies [79]. In contrast, it is still not completely
clear to what extent approaches, such as the measurement of
prostate-speciﬁc antigen in the serum, improve the patient’s
outcome [80].
Currently, most prognostic markers used in a routine
clinical setting are based on clinical parameters such as
performance status and stage and vary between cancer types
[84]. In addition, molecular markers such as the expression
of HER2/NEU have been established to further stratify
patients according to their relapse risk and their need for
additional therapies [85]. It is very likely that, in the near
future more sophisticated tools such as gene expression
proﬁles will become available [86].
Two major hurdles still hamper the wide spread use of
the above-mentioned early detectiontools in cancer care: (1)
the majority of patients fear invasive and time-consuming
proceduresand(2)costsofmoderndiagnostics.Accordingly,
there is a need for minimal invasive tools which are cost-
eﬀective, and the analysis of cancer-speciﬁc antibodies might
provide an acceptable solution to this clinical dilemma.
Such a role would certainly be complementary as serological
approaches are unlikely to replace “classical” pathological
markers or staging procedures.
In our opinion, the available data justiﬁes cautious
optimism regarding the development of serological analyses
into diagnostic and/or prognostic tools. Detailed analyses
of the human antibody repertoire will hopefully contribute
to clarifying the clinical value of such humoral responses.6 Clinical and Developmental Immunology
Combined data from these studies could vastly improve
the identiﬁcation and selection of appropriate diagnostic
and prognostic markers as well as of future targets for
immunotherapies [87, 88].
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